Endpoint Modernization in Registered Multiple Sclerosis Trials: A ClinicalTrials.gov Analysis of Progression-Sensitive, Biomarker, Patient-Reported, and Digital Outcomes
This analysis of ClinicalTrials.gov reveals that while registered Multiple Sclerosis trials have increasingly adopted patient-centered, cognitive, biomarker, and digital endpoints since 2010, they continue to rarely incorporate explicit measures of progression independent of relapse activity (PIRA) or smoldering disease biology, highlighting a significant gap between modern disease concepts and current trial design.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the world of Multiple Sclerosis (MS) research as a massive, global construction site. For decades, the foremen (researchers) have been using the same old blueprints to measure if a building is getting stronger or weaker. They mostly looked at two things: sudden storms (relapses, where symptoms flare up quickly) and visible cracks in the walls (inflammation seen on standard MRI scans).
However, scientists have recently realized that a building can also slowly crumble from the inside out, even when there are no storms and no obvious cracks. This is like "smoldering" damage—slow, silent progression that happens independently of the big, loud events.
This paper is a report card on how well the construction site has updated its blueprints to measure this "smoldering" damage. The authors went through the public registry of nearly 2,100 MS clinical trials (the "construction permits" filed between 2010 and 2026) to see what tools researchers are actually using to measure progress.
Here is what they found, broken down simply:
1. The "Old Tools" Are Still the Most Popular
Even though we know about the "smoldering" damage, most trials are still sticking to the classic checklist.
- Disability checks: About 35% of trials still rely heavily on standard disability scores (like checking if a patient can walk a certain distance).
- Storm counts: About 17% focus on counting relapses (the "storms").
- Standard X-rays: Another 17% look at standard MRI scans for inflammation.
2. The "New Tools" Are Being Added, But Slowly
The researchers looked for "modern" tools that could catch the silent, smoldering damage. These include:
- Smart sensors: Digital watches or apps that track daily life.
- Patient diaries: Asking patients how they feel, not just what a doctor sees.
- Brain shrinkage tests: Looking for atrophy (the brain getting smaller), which is a sign of slow damage.
- Blood/Spinal fluid tests: Looking for biological markers of damage.
The Good News: The use of these "modern, patient-centered" tools is growing. In the early 2010s, only about 64% of trials used at least one of these new methods. By 2026, that number jumped to 76%. It's like more construction sites are starting to use digital sensors and ask the workers how they feel.
The Bad News: Despite this growth, the specific tools designed to catch strictly the "smoldering" damage are still almost non-existent.
- Only 0.7% of all trials (just 15 out of 2,077) explicitly mentioned measuring "progression independent of relapse activity" (PIRA) or "smoldering progression."
- Even when looking at the broader category of "biological progression" (using advanced MRI or fluid biomarkers), the usage rate has stayed flat at around 16-17% for over a decade. It hasn't gone up, even as the science has advanced.
The Big Takeaway
Think of it like this: The construction site has started buying new, fancy tools (digital sensors, patient surveys, advanced blood tests), which is great. But, the foremen are rarely using these tools to specifically look for the "silent, smoldering fire" that happens between the big storms.
The paper concludes that while trial registries are becoming more modern and patient-friendly, there is a gap between what scientists now know about MS (that it can progress silently) and the actual language used in the trial plans. Most trials still don't explicitly say, "We are measuring the slow, silent damage that happens even when the patient isn't having a relapse."
In short: We are updating the toolbox, but we haven't fully updated the instruction manual to tell us how to use those tools to find the silent, smoldering disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.